Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Multicenter Phase 3B Follow-up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens One Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in the NeisVac-C Non-interference Study 216

NCT00161941 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00161941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00161941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Multicenter Phase 3B Follow-up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens One Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in the NeisVac-C Non-interference Study 216
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 30, 2003
Completion date
December 31, 2003
Enrollment
321
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal meninigitis, serogroup c